Krystal BiotechNASDAQ: KRYS

Krystal Biotech (KRYS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Krystal Biotech (KRYS) soars 36.5% on strong uptake of its newly approved drug Vyjuvek and encouraging pipeline progress.

Krystal Biotech, Inc. (NASDAQ: KRYS), a biotechnology company, will present new preclinical data on respiratory genetic medicine candidates KB407 and KB408 at the American Thoracic Society (ATS) 2024 International Conference in San Diego, California from May 17-22, 2024.

Krystal Biotech, Inc. (KRYS) reported quarterly earnings of $0.03 per share, falling short of the Zacks Consensus Estimate of $0.20 per share. This is an improvement from a loss of $1.76 per share in the same quarter last year.

Krystal Biotech (KRYS) is experiencing positive earnings estimate revisions and has a favorable Zacks Earnings ESP as we enter earnings season.

Krystal Biotech (KRYS) is a strong candidate for investors seeking stocks with potential for sustained growth, as it has been identified as one of the stocks meeting our criteria for recent price strength.

If you are looking for stocks that are well positioned to maintain their recent uptrend, Krystal Biotech (KRYS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

If you are looking for stocks that are well positioned to maintain their recent uptrend, Krystal Biotech, Inc. (KRYS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Krystal Biotech, Inc. (KRYS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.